Catalyst Pharmaceutical Partners Inc. is developing CP-690,550 in rheumatoid arthritis with Pfizer Inc. The name was incorrect in the July 20, 2009 issue.
Editor's note: The correction has been made in BioWorld Online.
To read more on related topics, click on one of the words below.